Research Analysts Issue Forecasts for ZVRA FY2025 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Equities researchers at Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Zevra Therapeutics in a report issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.24) per share for the year, down from their prior estimate of $1.88. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share.

ZVRA has been the topic of a number of other reports. Canaccord Genuity Group upped their target price on Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday. Finally, Guggenheim increased their price objective on Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and a consensus price target of $22.14.

Zevra Therapeutics Price Performance

Shares of NASDAQ ZVRA opened at $8.31 on Friday. The firm has a market capitalization of $449.70 million, a P/E ratio of -4.22 and a beta of 1.98. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock’s 50-day simple moving average is $7.93 and its two-hundred day simple moving average is $8.16. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%.

Insider Buying and Selling

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now directly owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 85,773 shares of company stock worth $674,176 in the last ninety days. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Woodline Partners LP lifted its holdings in Zevra Therapeutics by 2.2% in the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after buying an additional 90,940 shares during the period. Velan Capital Investment Management LP lifted its holdings in Zevra Therapeutics by 50.0% in the 4th quarter. Velan Capital Investment Management LP now owns 300,000 shares of the company’s stock worth $2,502,000 after buying an additional 100,000 shares during the period. Squarepoint Ops LLC lifted its holdings in Zevra Therapeutics by 36.1% in the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after buying an additional 4,384 shares during the period. ProShare Advisors LLC purchased a new stake in Zevra Therapeutics in the 4th quarter worth approximately $145,000. Finally, Millennium Management LLC lifted its holdings in Zevra Therapeutics by 138.2% in the 4th quarter. Millennium Management LLC now owns 233,132 shares of the company’s stock worth $1,944,000 after buying an additional 135,246 shares during the period. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.